These observations support the hypothesis that acquisition of TP53 or KRAS mutations provides MPN-BP ICs with a proliferative advantage, irrespective of the size of the mutant subclone present in the primary cells. The gene discussed is KRAS; the disease is myeloproliferative disorder.